Copertina

A subtype of cancer‐associated fibroblast expressing syndecan‐2 (SDC2) predicts survival and immune checkpoint inhibitor response in gastric cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ji‐Yong Sung, Jae‐Ho Cheong, Kihye Shin, Eui Tae Kim
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical and Translational Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

CD39 expression defines exhausted CD4+ T cells associated with poor survival and immune evasion in human gastric cancer
di: Zhen‐quan Duan, et al.
Pubblicazione: (2024)

Quantum biology: From mechanisms to medicine
di: Ji‐Yong Sung, et al.
Pubblicazione: (2026)

Tumour hepcidin levels as a biomarker for predicting response to immune checkpoint inhibition in advanced non‐small cell lung cancer
di: Yuichiro Suzukawa, et al.
Pubblicazione: (2026)

Bidirectional crosstalk between cancer cells and cancer‐associated fibroblasts in mixed organoid system elicits transcriptomic characteristics of pancreatic cancer with potential therapeutic vulnerabilities
di: Jae‐Il Choi, et al.
Pubblicazione: (2024)

Bilayer 3D co‐culture platform inducing the differentiation of normal fibroblasts into cancer‐associated fibroblast like cells: New in vitro source to obtain cancer‐associated fibroblasts
di: Yeon Ju Kim, et al.
Pubblicazione: (2024)

Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
di: Agnieszka Beata Malczewski, et al.
Pubblicazione: (2025)

A comprehensive analysis of the correlation between plasma cytokines/chemokines and tumor immune microenvironment signature influences the response of checkpoint inhibitors in advanced non‐small‐cell lung cancer
di: Van Hieu Mai, et al.
Pubblicazione: (2026)

New pathogen for gastric cancer: Streptococcus anginosus
di: Ruijie Zeng, et al.
Pubblicazione: (2024)

Spatial omics accelerate the study of cancer‐associated fibroblasts in non‐small lung cancer
di: Haozhen Liu, et al.
Pubblicazione: (2024)

Established a therapeutic response prediction model in metastatic gastric cancer by liquid biopsy
di: Sheng Liu, et al.
Pubblicazione: (2024)

An exosome‐based liquid biopsy signature for therapeutic response prediction in metastatic gastric cancer
di: Keisuke Okuno, et al.
Pubblicazione: (2024)

STK25 inhibits cancer‐associated fibroblast activation to overcome cetuximab resistance in colorectal cancer
di: Yifan Hou, et al.
Pubblicazione: (2026)

Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
di: Saira Afzal, et al.
Pubblicazione: (2024)

Exploring new frontiers in lung cancer treatment: The role of cancer‐associated fibroblasts (CAFs) and EGFR‐TKI resistance
di: Jiaqi Liang, et al.
Pubblicazione: (2025)

Stromal FAP + cancer associated fibroblasts orchestrate a pro‐tumorigenic niche with malignant proliferative stemness and cancer progression
di: Jiajin Wu, et al.
Pubblicazione: (2026)

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer
di: Yifan Cao, et al.
Pubblicazione: (2024)

Challenges and advances of immune checkpoint therapy
di: Lingyu Li, et al.
Pubblicazione: (2024)

Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours
di: Meghali Goswami, et al.
Pubblicazione: (2024)

scICB: A pan‐cancer database of human temporal immune checkpoint blockade therapy at single‐cell transcriptomic resolution
di: Fansen Ji, et al.
Pubblicazione: (2025)

High KRT17 expression in tumour budding indicates immunologically ‘hot’ tumour budding and predicts good survival in patients with colorectal cancer
di: Wenfeng Liang, et al.
Pubblicazione: (2024)

Distinct fibroblast subpopulations associated with bone, brain or intrapulmonary metastasis in advanced non‐small‐cell lung cancer
di: Ke Xu, et al.
Pubblicazione: (2024)

A new paradigm for cancer immunotherapy: Orchestrating type 1 and type 2 immunity for curative response
di: Bing Feng, et al.
Pubblicazione: (2024)

Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer
di: Eudald Felip, et al.
Pubblicazione: (2025)

A comprehensive atlas of pediatric immune checkpoint inhibitors‐related adverse events: From real‐world pharmacovigilance data to mechanistic insights
di: Anqi Lin, et al.
Pubblicazione: (2025)

Spatial distribution of immune cells and their proximity to STING+ cells are associated with survival in glioblastoma
di: Hanwool Jeon, et al.
Pubblicazione: (2025)

Deciphering of intra‐tumoural heterogeneity and the interplay between metastasis‐associated meta‐program and myofibroblasts in gastric cancer
di: Xiongyan Wu, et al.
Pubblicazione: (2025)

Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinoma
di: Yu‐Min Zhong, et al.
Pubblicazione: (2024)

Targeting CBP revers chemoresistance to 5‐FU of CDX2/REG4 double‐positive gastric cancer
di: Zhiyuan Fan, et al.
Pubblicazione: (2024)

Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma
di: Weijiao Xu, et al.
Pubblicazione: (2025)

Identification of hepatitis B virus infection and integration and its oncogenic role in gastric cancer
di: Mengge Li, et al.
Pubblicazione: (2024)

Low methylthioadenosine phosphorylase expression is associated with worse survival in patients with acute myeloid leukaemia
di: Yiyu Xiao, et al.
Pubblicazione: (2024)

Human tumour vessel heterogeneity in ovarian cancer and its association with response to neoadjuvant chemotherapy
di: Emmanuel M. Gabriel, et al.
Pubblicazione: (2024)

Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma
di: Fan Liu, et al.
Pubblicazione: (2025)

Single‐cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
di: Haoxin Peng, et al.
Pubblicazione: (2024)

PUS7‐dependent pseudouridylation of ALKBH3 mRNA inhibits gastric cancer progression
di: Yongxia Chang, et al.
Pubblicazione: (2024)

Epigenetic dynamics in gastric cancer precancerous lesions: From molecular mechanisms to precision risk stratification
di: Kewei Ma, et al.
Pubblicazione: (2025)

Distinct discrepancy in breast cancer organoids recapitulation among molecular subtypes revealed by single‐cell transcriptomes analysis
di: Ziqi Jia, et al.
Pubblicazione: (2024)

Metastasis ability, genomic profile, subtype characteristic and curative efficacy of multiple pulmonary hematogenous metastases in lung cancer
di: Liuer He, et al.
Pubblicazione: (2024)

Genotyping of RB1 status identifies two distinct subtypes in EGFR‐mutant lung cancers with SCLC transformation
di: Jie Huang, et al.
Pubblicazione: (2024)

Precision treatment paradigm: Genomic features and therapeutic implications in mesenchymal‐epithelial transition‐amplified gastric cancer
di: Yiyi Yu, et al.
Pubblicazione: (2024)